do i qualify for tirzepatide BMI Guidelines Eligibility bmi required for glp 1

Key information to disclose includes: Medication name and dose "I take Wegovy (semaglutide) 2.4 mg once weekly by subcutaneous injection" Duration of treatment how long you have been taking Wegovy and whether you are still in the dose-escalation phase Current side effects any ongoing nausea, vomiting, diarrhoea, dizziness, or other symptoms Reason for prescription whether prescribed for obesity alone or with comorbidities such as type 2 diabetes, hypertension, or cardiovascular disease Overall health status current weight, blood pressure, and general wellbeing Donation staff will ask about your medical history and may need to consult with medical advisors regarding Wegovy

Tirzepatide does not cause traditional withdrawal symptoms because it does not create physical dependence

Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated

5000mg of Glutathione: A master antioxidant that detoxifies, protects cells from free radical damage, and promotes a brighter, more even skin tone while reducing dark spots

As the TRIUMPH Phase 3 trials progress through 2026 and beyond, the full picture of retatrutides efficacy and safety profile will come into sharper focus

Results from Semaglutide weight loss treatments vary, but many patients notice significant changes within the first months